Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of RAY1225 Injection Sites
NCT06577428Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RAY1225 in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Raynovent Biotech. Primary endpoints: Area Under the Concentration Versus Time Curve from Time Zero to Infinity and Maximum Concentration. Started Jul 2024; status: completed.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06577428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577428.